Catalano et al (2011) evaluated the safety and short-term outcomes of a newly introduced drug-eluting ethmoid stent (the MicroFlow Spacer) in 23 patients with a total of 40 implanted ethmoid sinuses. Patients with medically refractory CRS were treated with patient-appropriate ESS, with the modification of treating the ethmoid sinuses with an ethmoid stent infused with triamcinolone, instead of conventional endoscopic ethmoidectomy. Patients were then followed-up over 6 months. Safety was determined by adverse events. Outcomes were assessed by interval changes in SNOT-20 and Lund-MacKay CT scores. Overall, the pre-operative SNOT-20 mean score was , versus post-operative score of , an improvement of that was both statistically (p < ) and clinically significant. Ethmoid-specific and side-specific Lund-MacKay mean scores both also showed statistically significant improvements. Pre-operative ethmoid-specific Lund-MacKay mean score was , versus post-operative score of , an improvement of (p < ). Pre-operative side-specific Lund-MacKay mean score was , compared with post-operative score of , an improvement of (p < ). There were no significant intra-operative or post-operative complications encountered. The authors concluded that the MicroFlow spacer appeared safe and effective in treating chronic ethmoid sinus disease within the defined follow-up period. They noted that the ability to deliver medication directly to diseased mucosa held wide-ranging potential. The findings of this small study need to be validated by well-designed studies with long-term follow-up.